In vitro drug testing based on contractile activity of C2C12 cells in an epigenetic drug model

Kazushi Ikeda, Akira Ito, Ryusuke Imada, Masanori Sato, Yoshinori Kawabe, Masamichi Kamihira

研究成果: ジャーナルへの寄稿学術誌査読

25 被引用数 (Scopus)

抄録

Skeletal muscle tissue engineering holds great promise for pharmacological studies. Herein, we demonstrated an in vitro drug testing system using tissue-engineered skeletal muscle constructs. In response to epigenetic drugs, myotube differentiation of C2C12 myoblast cells was promoted in two-dimensional cell cultures, but the levels of contractile force generation of tissue-engineered skeletal muscle constructs prepared by three-dimensional cell cultures were not correlated with the levels of myotube differentiation in two-dimensional cell cultures. In contrast, sarcomere formation and contractile activity in two-dimensional cell cultures were highly correlated with contractile force generation of tissue-engineered skeletal muscle constructs. Among the epigenetic drugs tested, trichostatin A significantly improved contractile force generation of tissue-engineered skeletal muscle constructs. Follistatin expression was also enhanced by trichostatin A treatment, suggesting the importance of follistatin in sarcomere formation of muscular tissues. These observations indicate that contractility data are indispensable for in vitro drug screening.

本文言語英語
論文番号44570
ジャーナルScientific reports
7
DOI
出版ステータス出版済み - 3月 16 2017

!!!All Science Journal Classification (ASJC) codes

  • 一般

フィンガープリント

「In vitro drug testing based on contractile activity of C2C12 cells in an epigenetic drug model」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル